$62.93 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About I-Mab

I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Stock Analysis

last close $73.24
1-mo return -7.3%
3-mo return 15%
avg daily vol. 457.05T
52-week high 85.4
52-week low 28.29
market cap. $5.3B
forward pe -
annual div. -
roe 26.2%
ltg forecast 25.9%
dividend yield -
annual rev. $1.5B
inst own. 38.3%

Subscribe now for daily local and international financial news